Hybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results.

Similar documents
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions

Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis

2-YEAR DATA SUPERA POPLITEAL REAL WORLD

Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA

Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)

Drug-Eluting Balloon Angioplasty versus Bare Metal Stents for Femoropopliteal Disease in Real-World Experience

The Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology

Do we really need a stent in long SFA lesions? No: DEB is the answer

SUPERSUB Trial: 1-yr outcomes of SUPERa SUBintimal stenting in CLI Patients

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report

DCB in my practice: How the evidence influences my strategy. Yang-Jin Park

Hybrid Procedures for Peripheral Obstructive Disease - Step by Step -

PATIENTS WITH CLI THE THREE YEARS OUTCOME OF ENDOLUMINAL BYPASS FOR PATIENTS WITH CLI

Step by step Hybrid procedures in peripheral obstructive disease. Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery

Comparing endoluminal bypass to open fem-pop bypasses; Final 1-year results of the SUPERB trial

The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio

BioMimics 3D in my Clinical Practice

Angiographic dissection pattern and patency outcomes of post balloon angioplasty for SFA lesions -a retrospective multi center analysis-

Novel hybrid nitinol ring stent (TIGRIS Gore)placement for atherosclerotic disease in the popliteal artery in 50 limbs

Medical therapy after angioplasty / stenting

The Final Triumph Of Endovascular Therapy In SFA Treatment

DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes

ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany

Extreme SFA Lesions: DETOUR I 12- Month Results in Lesions >30cm. Sean Lyden, MD Chairman Vascular Surgery Cleveland Clinic Cleveland, Ohio

Robert W. Fincher, DO The Ritz-Carlton, Dove Mountain Marana, Arizona February 7th, 2015

Brachytherapy for In-Stent Restenosis: Is the Concept Still Alive? Matthew T. Menard, M.D. Brigham and Women s Hospital Boston, Massachussetts

Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD

Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA

John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division

Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry

RESULTS OF VIABAHN IN AORTO ILIAC OCCLUSION

BIOFLEX PEACE Registry

Surgical Bypass or. Zilver PTX. 12 months preliminary data. LINC 2016, Leipzig. Marc Bosiers, MD. Marc Bosiers Koen Deloose Joren Callaert

The latest evidences from the DES trials in peripheral arterial disease

Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria

Atherectomy with thrombectomy of. Rotarex S : The Leipzig experience

Disclosures. Objectives. Bypass vs. Endo for SFA Disease: Reaching Consensus on a Rational Approach. Christopher D. Owens, MD 4/23/2009

Femoropopliteal Above-Knee Bypass: The True Results

Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial

TOBA II 12-Month Results Tack Optimized Balloon Angioplasty

How do I use mechanical debulking for the treatment of arterial occlusions

Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort

Lessons & Perspectives: What is the role of Cryoplasty in SFA Intervention?

Christian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide

When Outcomes Matter, Design Matters

Disclosures. In-Stent Restenosis: The Tail IS Wagging the Dog 4/15/2016. Restenosis: The Continuing Challenge for Peripheral Vascular Intervention

Koen Keirse, MD RZ Tienen, Belgium

PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA. Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE

Hypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis

Update in femoral angioplasty & stenting PRO

Disclosures. Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long?

Rotarex mechanical debulking: The Leipzig experience in patients

A Data-driven Therapeutic Algorithm For Choosing Among Currently Available Tools For SFA Intervention

BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort

Drug- Coated Balloons for the SFA: Overview of Technology and Results

4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters

Mid-term outcome of CERAB for aorto-iliac occlusive disease. Michel Reijnen Rijnstate Arnhem The Netherlands

Tools and options for recanalisation of long-femoro-popliteal segments

Disclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA

The incidence of peripheral artery disease (PAD)

Stratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI?

Wifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization

Atherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System

Or is the ivolution stent a better alternative? EVOLUTION 12-month data

Treatment Strategies for Long Lesions of greater than 20 cm

DEB in Periphery: What we Know Till Now

Utility of Image-Guided Atherectomy for Optimal Treatment of Ambiguous Lesions by Angiography

Cryoplasty versus conventional angioplasty in peripheral arterial disease: 3 year analysis of reintervention free survival by treatment received.

Balloon Expandable Covered Stents. Suddenly a Crowded Space

CLI Treatment Using Long and Scoring Balloons

Evidence-Based Optimal Treatment for SFA Disease

Maximizing Outcomes in a complex population with Drug-coated balloon

Accurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery

CHALLENGES IN FEMORO-POPLITEAL STENTING

The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan

The BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA

Pulsar stent technology

Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results

Endovascular Should Be Considered First Line Therapy

Excimer Laser angioplasty for femoro-popliteal disease. Sendai Kousei Hospital, Tokyo Kamata Hospital Naoto Inoue MD, FSCAI, FJCC, FAHA

Advancing treatment in highly complex lesions evidence and practice. Arne Schwindt St. Franziskushospital Münster

9/7/2018. Disclosures. CV and Limb Events in PAD. Challenges to Revascularization. Challenges. Answering the Challenge

The clinical outcome camparison between covered stent(cv) and drug-eluting balloon(deb) for SFA lesions: a single center result

DCB + BMS is not a DES

New Data to Shape the Era of Drug Elution in Peripheral Interventions

12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany

Vessel Preparation Prior to DCB and Stenting: How to Do It.

Mechanical thrombectomy in peripheral interventions: A multitask and effective tool in a widening scenario. Current evidence and technical tips.

In-Stent Restenosis: New Evidence From Laser + Drug Coated Balloons

The drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY

New Evidence from Laser + Drug Coated Balloons for Treatment of In-Stent Restenosis

PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014

Does stent design influence the results of SFA stenting?

Disclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are

Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD

The drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY

OCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter. Patrick Muck, MD

Lessons learnt from DES in the SFA is there any ideal concept so far?

Transcription:

Hybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results. Wronski J. 1), 2) 3), Wilczynski M 1), Gembal P 1), Milik K 1), Dec St 1), Grybos M 1) 1) Department of Vascular Surgery, Regional Hospital Mielec, Poland, 2) Department of Vascular Surgery, District Hospital Lublin, Poland 3) Department of Vascular Surgery and Angiology, Medical University, Lublin, Poland

Disclosure Speaker name: Jacek Wronski I do not have any potential conflict of interest

Valji K. Radiology Key Chapter 8 Origin of study Endovascular treatment of the femoro-popliteal segment is increasingly employed for treatment in patients suffering from PAD Self-expanding nitinol stents implanted to the popliteal artery have demonstrated high percentage of in-stent restenosis, stent occlusions and stent fractures

Tigris,Gore, technical data

Tigris,Gore, technical data

Aim of study The evaluation a 12 -months patency of the hybrid heparin-bonded nitinol and eptfe stent (Tigris, Gore) for treatment of atherosclerotic popliteal artery occlusion in a prospective, single center, analysis.

Study population Enrollment period January 2013 - May 2015 No. of consecutive patients treated by TIGRIS implantation No. of patients included to the study 49 Intermitted claudications or CLI ( Rutherford category) 3,4 ± 0,9 Average lesions lenght of occluded arteries 85 9,38 cm ( 2,5-30 cm) CTO 86% ( 42/49) TASC categories: TASC A 10% ( 5/49 ) TASC B 41% ( 20/49 ) TASC C 24,5% ( 12/49 ) TASC D 24,5% ( 12/49 ) Exclusion criteria No. of patients Lack of follow-up 19 Concomittant other stents implantations 17

Patient demographics Variable Age 70,2±10,56 Male gender 92% ( 45/49) Diabetes mellitus 22% ( 11/49) Cerebral ischemia 10% ( 5/49 ) Cardiac disease 12% ( 6/49) Renal disease 4% ( 2/49 )

Baseline lesions characteristics Anatomical lesion location Distal SFA to P1 30,6 % ( 15/49) Pop P1 14,3% ( 7/49) Pop P2 4% ( 2/49) Pop P3 2% ( 1/49) Pop P1-P2 22,5% ( 11/49) Pop P2-P3 12,2% ( 6/49) Pop P1-P3 14,3% ( 7/49)

Results ( 12-months follow-up overall/occluded popliteal group): Primary patency ( PP ) 68,5%/ 73,3% Freedom from Target Lesion Revascularisation ( TLR ) 81,6% ( 41/49)/ 86,7% Postoperated Rutherford category ( mean) 1,0±0,9 Change in Rutherford category pre/postop. ( mean) 2,4±1,0 Stent s fractures 0,0%

Results Overall the primary patency rates after 1,3,6 and 12 months were 98,0%, 93,8%, 87,5% and 68,5% respectivelly, in CTOs in the popliteal segment rate after 6 and 12 months was 93,3% and 73,3% respectivelly

Results Overall freedom from TLR after 1,3,6 and 12 months was 98,0%, 95,9%, 91,7% and 83,1% respectivelly, in patients with CTOs in popliteal segment after 6 and 12 months was 93,3% and 86,7% respectivelly

Comparision with other studies Study Type of study No. of patients/ occlusions CTO(%) in whole group Average lesions lenght ( mm) Hybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: midterm follow-up results. Prospective single center analysis n=49/ 42 Twelve-month experience with Gore Tigris Vascular stent in the superficial femoral and popliteal arteries. Piorkowski M et all. J Cardiovasc Surg 2015; 1: 89-95 Retrospective single center analysis Use of a new Hybrid Heparin- Bonded Nitinol Ring Stent in the popliteal artery procedural and mid-term clinical and anatomical outcomes. Parthipun A et all. Cardiovascular Intervent Radiol. 2015; 4: 846-54 Prospective singler center analysis n=32/2 n=48 / legs 50/occl. 37 Tigris Trial data Laird J Viva, September 2016, USA Oral presentation ( VascularNews) Prospective randomised multicenter study n=197/ 83 86% 5% 74,0% 42,1% 119,1±67,0 / 93,8 (25-300 ) Primary patency 68,5% / 73,3% Freedom from TLR 61,6%/ 86,7% 43,1±26 114,2±36,9 107,6±68,6 85,5±6,0% 69,5±6,0% 63% nd 86,1±5,9% nd

Conclusion Implantation of hybrid-heparin bonded nitinol and eptfe stent (GORE TIGRIS Vascular Stent) alleviated the need to perform revascularization in most patients with CTOs in popliteal segment, a lesion that previously had limited treatment options available.

Winter in Leipzig is beautiful Winter in Leipzig is beautiful

Hybrid Heparin-Bonded Nitinol and eptfe Stent in the treatment of popliteal artery occlusion: mid- term follow-up results. Wronski J. 1), 2) 3), Wilczynski M 1), Gembal P 1), Milik K 1), Dec St 1), Grybos M 1) 1) Department of Vascular Surgery, Regional Hospital Mielec, Poland, 2) Department of Vascular Surgery, District Hospital Lublin, Poland 3) Department of Vascular Surgery and Angiology, Medical University, Lublin, Poland